NCT01128855View on ClinicalTrials.gov

A Double-blind, Escalating Dose, Randomized, Placebo-controlled Study Assessing PK, Safety, Tolerability in Non-ambulant DMD Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 12, 2010

Primary Completion Date

October 25, 2011

Study Completion Date

October 25, 2011

Conditions
Muscular Dystrophies
Interventions
DRUG

3 mg/kg GSK2402968

Weekly subcutaneous injection

DRUG

6 mg/kg GSK2402968

Weekly subcutaneous injection

DRUG

9 mg/kg GSK2402968

Weekly subcutaneous injection

DRUG

12 mg/kg GSK2402968

Weekly subcutaneous injection

OTHER

Placebo

Weekly Placebo

Trial Locations (2)

43205

GSK Investigational Site, Columbus

75651

GSK Investigational Site, Paris

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01128855 - A Double-blind, Escalating Dose, Randomized, Placebo-controlled Study Assessing PK, Safety, Tolerability in Non-ambulant DMD Subjects | Biotech Hunter | Biotech Hunter